Revvity, Inc. (NYSE:RVTY) Receives $125.53 Average Price Target from Analysts

Revvity, Inc. (NYSE:RVTY) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $125.53.

A number of research analysts have issued reports on RVTY shares. Wells Fargo & Company started coverage on Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 target price for the company. Leerink Partners started coverage on shares of Revvity in a report on Monday, July 8th. They set an “outperform” rating and a $125.00 target price on the stock. Barclays lifted their price target on shares of Revvity from $115.00 to $125.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. increased their price objective on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Finally, Jefferies Financial Group boosted their price objective on shares of Revvity from $115.00 to $125.00 and gave the company a “hold” rating in a research report on Monday, July 29th.

Revvity Price Performance

Shares of Revvity stock opened at $121.51 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.98. The company has a market cap of $14.99 billion, a PE ratio of 100.42, a price-to-earnings-growth ratio of 3.35 and a beta of 1.05. The firm has a fifty day moving average price of $121.40 and a two-hundred day moving average price of $112.27. Revvity has a fifty-two week low of $79.50 and a fifty-two week high of $128.15.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The business had revenue of $691.70 million for the quarter, compared to analyst estimates of $690.33 million. During the same period in the previous year, the business earned $1.21 EPS. The firm’s revenue was down 2.5% on a year-over-year basis. Analysts expect that Revvity will post 4.75 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. Revvity’s payout ratio is currently 23.14%.

Insiders Place Their Bets

In other news, insider Tajinder S. Vohra sold 2,153 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the transaction, the insider now directly owns 23,960 shares of the company’s stock, valued at $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Tajinder S. Vohra sold 2,154 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the sale, the insider now owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,807 shares of company stock worth $937,576. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently made changes to their positions in the business. Rothschild Investment LLC purchased a new position in shares of Revvity during the 2nd quarter valued at $25,000. Logan Capital Management Inc. bought a new position in Revvity during the fourth quarter worth about $37,000. EverSource Wealth Advisors LLC increased its stake in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock worth $41,000 after purchasing an additional 167 shares in the last quarter. Family Firm Inc. purchased a new position in shares of Revvity in the second quarter worth about $43,000. Finally, Fairfield Financial Advisors LTD bought a new stake in shares of Revvity in the second quarter valued at approximately $43,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.